Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENESIS apalutamide study in metastatic castration-resistant prostate cancer
jRCTs051220077Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Primary endpoint: PSA response rate at 12 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs051220077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220077.